NCT04355936View on ClinicalTrials.gov

Telmisartan for Treatment of COVID-19 Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

May 19, 2020

Primary Completion Date

November 2, 2020

Study Completion Date

November 30, 2020

Conditions
COVID-19 Drug Treatment
Interventions
DRUG

Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.

Control arm will receive standard care.

Trial Locations (2)

1209

Hospital Español de Buenos Aires, Buenos Aires

C1120AAR

Hospital de Clínicas 'José de San Martín', Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires

Sponsors
All Listed Sponsors
collaborator

Carlos R. Rojo, MD

UNKNOWN

collaborator

Facultad de Medicina, Universidad de Buenos Aires, UBA

UNKNOWN

lead

Laboratorio Elea Phoenix S.A.

INDUSTRY